By Nicholas G. Miller
American depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease.
The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year.
The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041.
Write to Nicholas G. Miller at nicholas.miller@wsj.com
(END) Dow Jones Newswires
July 21, 2025 12:20 ET (16:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。